Angle Share News (AGL)

LONDON BROKER RATINGS: JPMorgan ups Rio Tinto; Redburn likes Carnival

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

EARNINGS UPDATES: Sylvania beats production goal, Angle revenue surges

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Angle launches tumour cell assay to "unlock" customised cancer care

(Alliance News) - Angle PLC on Monday announced the launch of its new Portrait Flex circulating tumour cell assay, which it said will provide valuable trial data and help advance "personalised cancer care."

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Angle hires Swansiger as new COO and Miller as new CSO

Angle PLC - Guildford, England-based liquid biopsy company - Hires Brett Swansiger as chief commercial officer and Karen Miller as chief scientific officer. Says Swansiger has over 20 years of experience within the molecular diagnostic and pharmaceutical industries. Most recently, he was COO at DxTerity Diagnostics, a biotechnology company based in the US. Says Miller brings a strong network of relationships within the pharmaceutical and companion diagnostic industries, having over 30 years of experience. She was most recently the CSO at Ixaka, a cell & gene therapy company. Start dates for both roles are undisclosed.

IN BRIEF: Angle customer to use biopsy products in clinical trial

Angle PLC - Guildford, England-based liquid biopsy company - Announces new contract with clinical-stage biotechnology company Artios Pharma for use of two DNA damage response assays in a Phase 1 clinical trial. Artios was Angle's first bespoke assay development customer, selecting it to develop immunofluorescence assays to detect biomarkers on tumour cells. The Phase 1 trial will begin "shortly" with completion expected around the end of 2024. Angle says the assays could later be used in larger and later-stage clinical trials.

IN BRIEF: Angle promotes Jan Groen to chair, replacing Garth Selvey

Angle PLC - Guildford, England-based liquid biopsy company - Chair Garth Selvey plans to retire from the board after interim results are released in September. Selvey has been chair since 2007. he will hand over the position of chair with immediate effect to Jan Groen, who is currently an independent non-executive director. Groen is also currently the chief executive officer and chair of Intravacc BV.

Angle losses widen in 'breakthrough year'

(Sharecast News) - Liquid biopsy specialist Angle described a "breakthrough year" in its 2022 results on Friday, with both FDA clearance and positive results from the ovarian cancer study being achieved.

Angle loss widens in 2022 despite being "breakthrough" year

(Alliance News) - Angle PLC on Friday said it had a "breakthrough" year, despite reporting an annual widened loss.

TRADING UPDATES: Angle partners with BioView; First Class hails nickel

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Datalex and SpaceandPeople extend deals

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

LONDON MARKET CLOSE: Stocks make headway thanks to retailers

(Alliance News) - Stock prices in London closed higher, buoyed by optimism from strong retail updates, and shaking off hawkishness from the US Federal Reserve.

Tougher market conditions impacting Angle clients

(Sharecast News) - Liquid biopsy specialist Angle said in an update on Thursday that actions taken to control its cost base, and the closure of its Canadian operations, left it on track to deliver expected cost savings of £2.6m in 2023 and £4m per annum after that.